Abstract:
A novel 2-imino-1,3-thiazoline-based compound is provided to show excellent T-type calcium channel inhibitory activity, thereby being useful as a therapeutic agent of diseases related to over-expression of a T-type calcium channel. A 2-imino-1,3-thiazoline-based compound is represented by a formula(1), wherein R1 is H or C1-5 linear or branched alkyl; each R2, R3, and R4 is independently H, halogen, C1-5 linear or branched alkyl, C1-5 alkyloxy, trifluoromethyl, trifluoromethoxy, phenyloxy, amino, methanesulfoneamino, para-toluene sulfone amino, nitro, C1-5 cyano alkyl, cyano, ethoxycarbonyl, or C3-12 cycloalkyl; R5 is C1-5 linear or branched alkyl, C3-6 cycloalkyl, or benzyl; R6 is C3-12 cycloalkyl, C4-17 alkylcycloalkyl, adamantyl, benzyl or C8-13 benzylalkyl; each n and m is 0 or 1; HX may exist or may not exist; and X is halogen when the HX exists. A composition for treating or preventing pain, epilepsy, hypertension, angina pectoris, arrhythmia and cancer comprises the compound as an effective ingredient.
Abstract:
A novel thiazole-based compound is provided to inhibit T-type calcium channel without side effects, so that the compound is useful for treating diseases associated with overexpression of T-type calcium channel including nociception, epilepsy, hypertension, angina pectoris, myocardial disease, vascular diseases and cancer. A novel thiazole-based compound having inhibitory effects on T-type calcium channel is represented by the formula(1), wherein R and R' are the same or different, and hydrogen atom, halogen atom, C1-C5 alkyl, alkyloxy, phenyloxy, nitro, cyano, alkoxycarbonyl or C3-C6 cycloalkyl; and X is halogen atom. An inhibitor of T-type calcium channel comprises the thiazole-based compound represented by the formula(1) or pharmaceutically acceptable salt thereof. A composition for preventing or treating diseases associated with overexpression of T-type calcium channel comprises the thiazole-based compound represented by the formula(1) or pharmaceutically acceptable salt thereof. Further, the diseases are one or more selected from a group consisting of pain, a fluke, a high blood pressure, angina pectoris and cancer.
Abstract:
An aryl ureido acetate-based compound and a composition for prevention or treatment of neurodegenerative disease containing the same compound are provided to inhibit activity of beta-amyloid and microglia without side effects, so that the neurodegenerative disease caused by beta-amyloid formation is prevented or treated. An aryl ureido acetate-based compound represented by the formula(1), formula(2) or formula(3) is provided, wherein X is S or NH; R1 is hydrogen, C1-C5 alkyl group or nitro group; R2 is hydrogen, C1-C5 alkyl group or C1-C5 alkoxy group; and R3 is hydrogen, C1-C5 alkyl group or halogen atom. The composition for prevention or treatment of neurodegenerative disease including Alzheimer's disease, dementia and Parkinson's disease contains the aryl ureido acetate-based compound, or pharmaceutically acceptable salts thereof and has a formulation selected from granule, lotion, powder, syrup, solution, aerosol, ointment, fluid extract, emulsion, suspension, impregnant, tablet, injection, capsule and pill.
Abstract:
본 발명은 (a) 리빙 음이온 중합에 의해 분자량 500 내지 100,000으로 조절된 폴리에틸렌옥사이드를 제공하는 단계, (b) 상기 제조한 폴리에틸렌옥사이드의 사슬 말단을 산과 반응시키거나, 슬톤, 에틸렌 술파이드 또는 프로필렌 술파이드, 트리멜리틱 안히드라이드 클로라이드, 메타크릴로일 클로라이드 또는 3-브로모이소부티릴 브로마이드와 고진공 하에서 반응시켜 사슬 말단 기능성화된 폴리에틸렌옥사이드를 제조하는 단계, (c) 상기 단계에서 기능성화된 폴리에틸렌옥사이드의 일부를 마크로모노머 및 마크로개시제로 사용하여 물 또는 유기 비극성/극성 용매 상에서 리빙 중합에 의해 그라프트 또는 블록 공중합체를 제조하는 단계 및 (d) 단계 (b)와 (c)에서 제조된 화학식 1 내지 4의 고분자 물질로부터 선택되는 고분자 물질과 금속염 용액을 환원제의 존재 하에 반응시켜 금속 입자 또는 금속염을 제조하는 단계를 포함하는 나노 크기 전이 금속 또는 금속염의 제조 방법에 관한 것이다. 본 발명에 의하면, pH와 열응답성 기능을 갖는 폴리에틸렌옥사이드계 그라프트 및 블록 공중합체의 제조가 용이하며, 고분자 약물도 용이하게 제조할 수 있으며, 이들을 사용하여 안정화시킨 전이금속 또는 금속염 나노 입자는 조영 효과 및 항암제의 전달 체계에 유용하게 사용될 수 있는 신소재 개발의 새로운 전기를 마련할 수 있을 것으로 기대된다. 사슬 말단 기능성화, 폴리에틸렌옥사이드, 나노 크기 전이금속, 금속염